BEP Chemotherapy (Bleomycin, Etoposide, Cisplatin)
Treatment for Testicular Cancer
Typical Dosage: Cisplatin 20mg/m2 days 1-5; Etoposide 100mg/m2 days 1-5; Bleomycin 30 units days 1, 8, 15 (every 21 days)
Effectiveness
90%
Safety Score
25%
Clinical Trials
8
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
25
DangerousModerateSafe
Treatment Details
Dosage Range
Cisplatin 20mg/m2 days 1-5; Etoposide 100mg/m2 days 1-5; Bleomycin 30 units days 1, 8, 15 (every 21 days)
Time to Effect
Weeks to months
Treatment Duration
9-12 weeks (3-4 cycles)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$25,000
Monitoring:$7,000
Side Effect Mgmt:$10,000
Total Annual:$42,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
20
Outcome-Based Costs
Cost per Responder
$49,412
Cost per Remission
$52,500
BEP Chemotherapy (Bleomycin, Etoposide, Cisplatin) Outcomes
for Testicular Cancer
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+80%
Common Side Effects
Nausea/Vomiting
+85%
Fatigue
+90%
Hair Loss
+100%
Myelosuppression (Neutropenia)
+70%
Nephrotoxicity
+40%
Ototoxicity
+40%
Neuropathy (peripheral)
+40%
Pulmonary fibrosis (Bleomycin)
+5%
Infertility
+60%
Active Clinical Trials
1 active trial recruiting for BEP Chemotherapy (Bleomycin, Etoposide, Cisplatin) in Testicular Cancer
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
NCT02341989ACTIVE NOT RECRUITINGPHASE3
348 participants
INTERVENTIONAL
Trondheim, Norway +1 more
Started: Apr 8, 2015
Completed Clinical Trials
6 completed trials for BEP Chemotherapy (Bleomycin, Etoposide, Cisplatin) in Testicular Cancer
Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours
NCT01726374COMPLETEDPHASE3
246 participants
INTERVENTIONAL
London, United Kingdom +34 more
Started: Feb 1, 2010
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
NCT00104676COMPLETEDPHASE3
263 participants
INTERVENTIONAL
Houston, United States +23 more
Started: Nov 26, 2003
Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors
NCT00301782COMPLETEDPHASE2
88 participants
INTERVENTIONAL
Birmingham, United Kingdom +19 more
Started: Jun 1, 2005
Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors
NCT00453232COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Cambridge, United Kingdom +6 more
Started: Aug 1, 2004
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
NCT00003941COMPLETEDPHASE3
222 participants
INTERVENTIONAL
Vienna (Wien), Austria +36 more
Started: Apr 1, 1999
Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors
NCT00002596COMPLETEDPHASE3
270 participants
INTERVENTIONAL
Anniston, United States +152 more
Started: Sep 1, 1994